Major binary events like late-stage clinical trial results or drug approvals offer high-risk, high-reward opportunities for those who can stomach the uncertainty.
News & Analysis: Global Blood Therapeutics
The company's most advanced drug has taken a step toward FDA approval.
Find out how earnings hurt some of these stocks.
Updated data from a late-stage trial of voxelotor fell shy of investors' expectations.
Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.
Investors hope that its lead drug candidate can make it to the Food and Drug Administration for approval soon.
The company reported boring third-quarter 2018 operating results, but followed up with important clinical updates in the first week of December.
Positive trial data unveiled at the American Society of Hematology conference makes these top stocks to watch in 2019.
Shares jump after the company releases upbeat clinical data and regulatory news.
If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.